Pfizer Vaccine Disappoints in Children Ages 2 to 5 Years

FRIDAY, Dec. 17, 2021 (HealthDay News) -- Two doses of a pediatric Pfizer-BioNTech COVID-19 vaccine failed to spur an adequate immune response in children ages 2 to 5 years, the companies announced Friday.
The pediatric trials used a 3-µg dose of the vaccine -- equivalent to about one-tenth of the dose used in adult shots. And while two 3-µg doses produced a good immune response in babies and children between 6 months and 2 years of age -- similar to that seen in people ages 16 to 25 years -- they failed to do so in the 2- to 5-year age group, the companies said in a statement.
Pfizer-BioNTech says they will try a third dose to see if that produces a more robust response, but they have no plans to try any amount of vaccine above 3 µg. Children younger than 5 years will get the third dose two months after they have received their second.
There is a building consensus that three doses of vaccine, not two, offers the best defense against COVID-19, including newer variants such as omicron.
Besides the ongoing trials in very young children, Pfizer-BioNTech is also conducting trials of three doses of 10 µg of COVID-19 vaccine (one-third of the dosage used in adults) in children ages 5 through 12 years, the companies said. They hope to complete the trials and ask for U.S. Food and Drug Administration authorization of a three-dose vaccine series in younger children sometime in the spring of 2022.
Related Posts
Acral Lentiginous Melanoma Survival Varies by Race, SES
MONDAY, Feb. 14, 2022 (HealthDay News) -- Acral lentiginous melanoma (ALM)...
Moderna Says Its COVID Vaccine Works Well in Children Aged 6 to 11
MONDAY, Oct. 25, 2021 (HealthDay News) -- Moderna announced Monday that its...
Alzheimer’s Genes Might Also Raise Odds for Epilepsy
THURSDAY, May 25, 2023 (HealthDay News) – People with a genetic predisposition...
